<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.1 20151215//EN" "https://jats.nlm.nih.gov/publishing/1.1/JATS-journalpublishing1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" specific-use="sps-1.9" dtd-version="1.1" xml:lang="pt" article-type="editorial">
  <front>
    <journal-meta>
      <journal-id journal-id-type="publisher-id">abc</journal-id>
      <journal-title-group>
        <journal-title>Arquivos Brasileiros de Cardiologia</journal-title>
        <abbrev-journal-title abbrev-type="publisher">Arq. Bras. Cardiol.</abbrev-journal-title>
      </journal-title-group>
      <issn pub-type="ppub">0066-782X</issn>
      <issn pub-type="epub">1678-4170</issn>
      <publisher>
        <publisher-name>Sociedade Brasileira de Cardiologia - SBC</publisher-name>
        <publisher-loc>S&#227;o Paulo, SP, Brazil</publisher-loc>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="publisher-id" specific-use="scielo-v3">yzqTS5YwYSQ57Ys48KqTgHH</article-id>
      <article-id pub-id-type="publisher-id" specific-use="scielo-v2">S0066-782X2013003100001</article-id>
      <article-id pub-id-type="publisher-id" specific-use="scielo-v1">S0066-782X(13)10100500001</article-id>
      <article-id pub-id-type="doi">10.5935/abc.20130224</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Editorial</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Realce tardio mioc&#225;rdico pela resson&#226;ncia magn&#233;tica card&#237;aca na Hipertens&#227;o Arterial Pulmonar: um marcador da gravidade da doen&#231;a</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Rochitte</surname>
            <given-names>Carlos Eduardo</given-names>
          </name>
          <xref ref-type="aff" rid="aff01"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Hoette</surname>
            <given-names>Susana</given-names>
          </name>
          <xref ref-type="aff" rid="aff02"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Souza</surname>
            <given-names>Rog&#233;rio</given-names>
          </name>
          <xref ref-type="aff" rid="aff02"/>
        </contrib>
      </contrib-group>
      <aff id="aff01">
        <addr-line>
          <named-content content-type="state"/>
        </addr-line>
        <institution content-type="orgname">Instituto do Cora&#231;&#227;o</institution>
        <institution content-type="orgdiv1">Setor de Resson&#226;ncia Magn&#233;tica e Tomografia Computadorizada Cardiovascular </institution>
        <country country="BR">Brazil</country>
      </aff>
      <aff id="aff02">
        <addr-line>
          <named-content content-type="city">S&#227;o Paulo</named-content>
          <named-content content-type="state">S&#227;o Paulo</named-content>
        </addr-line>
        <institution content-type="orgname">Universidade de S&#227;o Paulo</institution>
        <institution content-type="orgdiv1">Hospital das Cl&#237;nicas </institution>
        <institution content-type="orgdiv2">Instituto do Cora&#231;&#227;o</institution>
        <country country="BR">Brazil</country>
      </aff>
      <pub-date date-type="collection" publication-format="electronic">
        <month>11</month>
        <year>2013</year>
      </pub-date>
      <volume>101</volume>
      <issue>5</issue>
      <fpage>377</fpage>
      <lpage>378</lpage>
      <permissions>
        <license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc/4.0/" xml:lang="en">
          <license-p>This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.</license-p>
        </license>
      </permissions>
      <pub-date publication-format="electronic" date-type="pub">
        <day>13</day>
        <month>12</month>
        <year>2013</year>
      </pub-date>
    </article-meta>
  </front>
  <body>
    <p>
      <bold>EDITORIAL</bold>
    </p>
    <p>
      <bold>Realce tardio mioc&#225;rdico pela resson&#226;ncia magn&#233;tica card&#237;aca na Hipertens&#227;o Arterial Pulmonar: um marcador da gravidade da doen&#231;a</bold>
    </p>
    <p>
      <bold>Carlos Eduardo Rochitte<sup>I</sup>; Susana Hoette<sup>II</sup>; Rog&#233;rio Souza<sup>II</sup></bold>
    </p>
    <p><sup>I</sup>Instituto do Cora&#231;&#227;o, InCor, Setor de Resson&#226;ncia Magn&#233;tica e Tomografia Computadorizada Cardiovascular </p>
    <p><sup>II</sup>Unidade de Circula&#231;&#227;o Pulmonar, Pneumologia, Instituto do Cora&#231;&#227;o do Hospital das Cl&#237;nicas da FMUSP, S&#227;o Paulo, SP - Brasil</p>
    <p>
      <xref ref-type="corresp" rid="end">Correspond&#234;ncia</xref>
    </p>
    <p><bold>Palavras-chave:</bold> Espectroscopia de Resson&#226;ncia Magn&#233;tica/m&#233;todos; Hipertens&#227;o Pulmonar; Mioc&#225;rdio, Fibrose Endomioc&#225;rdica.</p>
    <p>O estudo de Bessa e cols.<sup>1</sup>, publicado neste n&#250;mero do <italic>Arquivo Brasileiro de Cardiologia</italic>, estudou 30 pacientes com Hipertens&#227;o Pulmonar (HP) com resson&#226;ncia card&#237;aca. Eles avaliaram a presen&#231;a e a extens&#227;o de realce tardio nesses pacientes e correlacionaram o percentual da massa de realce tardio com marcadores de gravidade na hipertens&#227;o pulmonar. O realce tardio foi encontrado em 93% dos pacientes com HP nos septos anterior e inferior, nas &#225;reas de inser&#231;&#227;o da parede livre do VD no septo, comumente chamado de realce tardio de padr&#227;o jun&#231;&#227;o ventricular. A massa de realce tardio foi corrigida para a massa do ventr&#237;culo esquerdo, sendo ent&#227;o utilizado o percentual de realce tardio para an&#225;lise. O presente estudo conseguiu mostrar maior percentual de fibrose mioc&#225;rdica nos pacientes com sinais de Insufici&#234;ncia Card&#237;aca Direita (IVD), Classe Funcional (CF) IV, Teste de Caminhada de 6 Minutos (TC6M) &lt; 300 m, &#237;ndice card&#237;aco (IC) &lt; 2,0 e press&#227;o de &#225;trio direito &gt; 15. A presen&#231;a de IVD, o comprometimento da CF e da dist&#226;ncia percorrida no TC6M e o IC baixo s&#227;o marcadores cl&#225;ssicos de progn&#243;stico na HP. O percentual de fibrose foi capaz de identificar os pacientes com IVD (avalia&#231;&#227;o cl&#237;nica), CF IV, TC6M &lt; 300 m e IC &lt; 2,0 L/min.m<sup>2</sup> com boa acur&#225;cia.</p>
    <p>Apesar dos avan&#231;os no conhecimento da fisiopatologia da doen&#231;a e na descoberta de novos tratamentos nas &#250;ltimas d&#233;cadas, a hipertens&#227;o pulmonar continua sendo uma doen&#231;a com progn&#243;stico sombrio<sup>2</sup>. Marcadores n&#227;o invasivos que avaliem melhor a gravidade da doen&#231;a e que possam ajudar a determinar os pacientes que necessitem de tratamento mais agressivo s&#227;o necess&#225;rios. O realce tardio &#233; uma ferramenta que foi inicialmente utilizada para a avalia&#231;&#227;o de &#225;reas de fibrose mioc&#225;rdica em pacientes que tiveram infarto do mioc&#225;rdio. O contraste injetado &#233; rapidamente lavado em &#225;reas normais, mas quando existe aumento do tecido extracelular, como ocorre na fibrose, o contraste fica retido e tem elimina&#231;&#227;o mais lenta desses locais. Quando imagens s&#227;o adquiridas tardiamente (5 a 10 min ap&#243;s a inje&#231;&#227;o do contraste), as &#225;reas que t&#234;m mioc&#225;rdio intacto n&#227;o ret&#234;m contraste, mas as &#225;reas que t&#234;m fibrose ret&#234;m o contraste, por isso o termo realce tardio.</p>
    <p>Em pacientes com HP, tr&#234;s estudos demonstraram a presen&#231;a de realce tardio na maioria dos pacientes avaliados, e o realce tardio foi encontrado principalmente na regi&#227;o da inser&#231;&#227;o do VD no septo e na parede septal<sup>3-5</sup>. A fibrose nessas &#225;reas tamb&#233;m pode ser encontrada frequentemente tamb&#233;m na miocardiopatia hipertr&#243;fica<sup>6,7</sup>, diferentemente de outras cardiomiopatias como a chag&#225;sica<sup>8</sup>, com predom&#237;nio da fibrose na parede inferolateral basal e apical do Ventr&#237;culo Esquerdo (VE), ou a miocardite viral, com padr&#227;o difuso<sup>9</sup>, entre outros padr&#245;es sugestivos de etiologias espec&#237;ficas de cardiomiopatias. Na maioria dessas doen&#231;as a presen&#231;a de realce tardio parece estar associada ao maior risco de arritmias e pior progn&#243;stico. O realce tardio mioc&#225;rdico (fibrose) de padr&#227;o jun&#231;&#227;o ventricular parece estar associado a sobrecarga do Ventr&#237;culo Direito (VD). A hip&#243;tese para essa localiza&#231;&#227;o preferencial do realce tardio est&#225; na sobrecarga sofrida pelo septo com o aumento da p&#243;s-carga do VD. Conforme aumenta a sobrecarga do VD esse dilata e empurra o septo em dire&#231;&#227;o ao VE sobrecarregando as &#225;reas de inser&#231;&#227;o do VD no septo e o pr&#243;prio septo. Shehata e cols demonstraram a rela&#231;&#227;o inversa da massa de realce tardio com o &#205;ndice de Excentricidade (IE), ou seja, quanto maior o abaulamento septal em dire&#231;&#227;o ao VE, e consequentemente menor o IE, maior era a massa de realce tardio<sup>10</sup>. Em estudos experimentais, essas s&#227;o as &#225;reas que s&#227;o submetidas a estresse m&#225;ximo numa contra&#231;&#227;o ventricular normal, e tamb&#233;m s&#227;o essas &#225;reas as primeiras a produzir pept&#237;deo natriur&#233;tico do tipo A em modelos de HP, refletindo maior estresse mec&#226;nico. O presente estudo de Bessa e cols. demonstrou que a maioria dos pacientes com HP tinha realce tardio e de padr&#227;o jun&#231;&#227;o ventricular, confirmando os dados da literatura<sup>1</sup>. Em estudo com ecocardiografia em pacientes com HP de etiologia espec&#237;fica, associada a esquistossomose, demonstrou-se tamb&#233;m uma rela&#231;&#227;o do aumento de press&#227;o pulmonar com a gravidade da doen&#231;a, sugerindo que em v&#225;rias etiologias de HP possa haver realce tardio de padr&#227;o semelhante<sup>11</sup>.</p>
    <p>Um ponto forte desse estudo foi que todos os pacientes tiveram um cateterismo card&#237;aco direito realizado em at&#233; 72 horas da realiza&#231;&#227;o da resson&#226;ncia card&#237;aca. Estudos pr&#233;vios demonstraram a rela&#231;&#227;o da massa de realce tardio com disfun&#231;&#227;o do VD e vari&#225;veis hemodin&#226;micas, mas o presente estudo foi o primeiro a demonstrar rela&#231;&#227;o da fibrose mioc&#225;rdica com marcadores cl&#237;nicos, hemodin&#226;micos e funcionais.</p>
    <p>A avalia&#231;&#227;o da fun&#231;&#227;o ventricular direita vem surgindo como um marcador progn&#243;stico independente na HP e o estudo de Shehata e cols<sup>10</sup>. tamb&#233;m demonstrou correla&#231;&#227;o inversa da massa de realce tardio com a fra&#231;&#227;o de eje&#231;&#227;o do VD<sup>10</sup>. Infelizmente, o presente estudo n&#227;o avaliou o percentual de massa de fibrose em rela&#231;&#227;o &#224; disfun&#231;&#227;o do VD.</p>
    <p>Apesar de esse estudo ter avaliado um n&#250;mero pequeno de pacientes com HP e ser um estudo transversal, n&#227;o sendo poss&#237;vel mostrar o papel progn&#243;stico do realce tardio, o fato de o percentual de fibrose estar aumentado em pacientes que t&#234;m os marcadores de pior progn&#243;stico sugere que o realce tardio possa vir a ser um marcador progn&#243;stico n&#227;o invasivo importante em pacientes com HP. Seria interessante se os autores fizessem o seguimento em longo prazo desses pacientes, para que o papel progn&#243;stico do realce tardio seja confirmado e a fibrose venha a mostrar seu papel progn&#243;stico na HP, ajudando na tomada de decis&#245;es cl&#237;nicas. O estudo de Bessa e cols. abre tamb&#233;m a possibilidade de se comparar outras formas de HP, como as pertencentes aos demais grupos da classifica&#231;&#227;o (secund&#225;ria a disfun&#231;&#227;o ventricular esquerda, a doen&#231;as do par&#234;nquima pulmonar, ao tromboembolismo pulmonar cr&#244;nico, por exemplo), a fim de se analisar a exist&#234;ncia ou n&#227;o de diferentes padr&#245;es de fibrose.</p>
    <p>Apesar dessas limita&#231;&#245;es, o artigo de Bessa e cols. &#233; mais uma contribui&#231;&#227;o cient&#237;fica original indicando que a fibrose mioc&#225;rdica detectada pela resson&#226;ncia card&#237;aca se correlaciona diretamente com a gravidade da doen&#231;a e, possivelmente, com o progn&#243;stico. Portanto, reafirma-se mais um marcador de gravidade da cardiomiopatia associada a hipertens&#227;o pulmonar que pode ser identificado pela resson&#226;ncia magn&#233;tica. A avalia&#231;&#227;o da fibrose mioc&#225;rdica intersticial pelo mapeamento T1 do mioc&#225;rdico por resson&#226;ncia poder&#225; no futuro trazer ainda maiores informa&#231;&#245;es sobre o estado do mioc&#225;rdio e progn&#243;stico nesse importante e desafiador cen&#225;rio cl&#237;nico.</p>
    <p>
      <fn id="end" fn-type="corresp">
        <label>
          <bold>Correspond&#234;ncia:</bold>
        </label>
        <p> Carlos Eduardo Rochitte </p>
        <p> Instituto do Cora&#231;&#227;o, InCor, HCFMUSP - Setor de Resson&#226;ncia Magn&#233;tica e Tomografia Computadorizada Cardiovascular </p>
        <p> Av. Dr. En&#233;as de Carvalho Aguiar, 44 - Andar AB, Cerqueira C&#233;sar </p>
        <p> CEP 05403-000, S&#227;o Paulo, SP - Brasil </p>
        <p> E-mail: </p>
        <p>
          <email xlink:href="rochitte@gmail.com">rochitte@gmail.com</email>
        </p>
      </fn>
    </p>
    <p>Artigo recebido em 23/10/13; revisado em 23/10/13; aceito em 23/10/13.</p>
  </body>
  <back>
    <ref-list>
      <ref id="B1">
        <mixed-citation>1. Bessa LG, Junqueira FP, Bandeira ML, Garcia MI, Xavier SS, Lavall G, et al. Pulmonary arterial hypertension: Use of delayed contrast-enhanced cardiovascular magnetic resonance in risk assessment. Arq Bras Cardiol.2013;Aug 27.pii S0066-782X2013005000069  [Epub ahead of print ]</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Pulmonary arterial hypertension: Use of delayed contrast-enhanced cardiovascular magnetic resonance in risk assessment</article-title>
          <source>Arq Bras Cardiol</source>
          <date>
            <year>2013</year>
            <day>27</day>
            <month>08</month>
          </date>
          <person-group person-group-type="author">
            <name>
              <surname>Bessa</surname>
              <given-names>LG</given-names>
            </name>
            <name>
              <surname>Junqueira</surname>
              <given-names>FP</given-names>
            </name>
            <name>
              <surname>Bandeira</surname>
              <given-names>ML</given-names>
            </name>
            <name>
              <surname>Garcia</surname>
              <given-names>MI</given-names>
            </name>
            <name>
              <surname>Xavier</surname>
              <given-names>SS</given-names>
            </name>
            <name>
              <surname>Lavall</surname>
              <given-names>G</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B2">
        <mixed-citation>2. Cicero C, Franchi SM, Barreto AC, Lopes AA. Lack of tight association between quality of life and exercise capacity in pulmonary arterial hypertension. Arq Bras cardiol.2012;99(4):876-85.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Lack of tight association between quality of life and exercise capacity in pulmonary arterial hypertension</article-title>
          <source>Arq Bras cardiol</source>
          <date>
            <year>2012</year>
          </date>
          <fpage>876</fpage>
          <lpage>85</lpage>
          <issue>4</issue>
          <volume>99</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Cicero</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Franchi</surname>
              <given-names>SM</given-names>
            </name>
            <name>
              <surname>Barreto</surname>
              <given-names>AC</given-names>
            </name>
            <name>
              <surname>Lopes</surname>
              <given-names>AA</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B3">
        <mixed-citation>3. Blyth KG, Groenning BA, Martin TN, Foster JE, Mark PB, Dargie HJ, et al. Contrast enhanced-cardiovascular magnetic resonance imaging in patients with pulmonary hypertension. <italic>Eur Heart J</italic>. 2005;26(19):1993-9.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Contrast enhanced-cardiovascular magnetic resonance imaging in patients with pulmonary hypertension</article-title>
          <source>Eur Heart J</source>
          <date>
            <year>2005</year>
          </date>
          <fpage>1993</fpage>
          <lpage>9</lpage>
          <issue>19</issue>
          <volume>26</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Blyth</surname>
              <given-names>KG</given-names>
            </name>
            <name>
              <surname>Groenning</surname>
              <given-names>BA</given-names>
            </name>
            <name>
              <surname>Martin</surname>
              <given-names>TN</given-names>
            </name>
            <name>
              <surname>Foster</surname>
              <given-names>JE</given-names>
            </name>
            <name>
              <surname>Mark</surname>
              <given-names>PB</given-names>
            </name>
            <name>
              <surname>Dargie</surname>
              <given-names>HJ</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B4">
        <mixed-citation>4. Junqueira FP, Macedo R, Coutinho AC, Loureiro R, De Pontes PV, Domingues RC,et al. Myocardial delayed enhancement in patients with pulmonary hypertension and right ventricular failure: Evaluation by cardiac mri. Br J Radiol.2009;82(982):821-6.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Myocardial delayed enhancement in patients with pulmonary hypertension and right ventricular failure: Evaluation by cardiac mri</article-title>
          <source>Br J Radiol</source>
          <date>
            <year>2009</year>
          </date>
          <fpage>821</fpage>
          <lpage>6</lpage>
          <issue>982</issue>
          <volume>82</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Junqueira</surname>
              <given-names>FP</given-names>
            </name>
            <name>
              <surname>Macedo</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Coutinho</surname>
              <given-names>AC</given-names>
            </name>
            <name>
              <surname>Loureiro</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>De Pontes</surname>
              <given-names>PV</given-names>
            </name>
            <name>
              <surname>Domingues</surname>
              <given-names>RC</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B5">
        <mixed-citation>5. McCann GP, Gan CT, Beek AM, Niessen HW, Vonk Noordegraaf A, van Rossum AC. Extent of mri delayed enhancement of myocardial mass is related to right ventricular dysfunction in pulmonary artery hypertension.AJR Am J Roentgenol.2007;188(2):349-55.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Extent of mri delayed enhancement of myocardial mass is related to right ventricular dysfunction in pulmonary artery hypertension: AJR Am</article-title>
          <source>J Roentgenol</source>
          <date>
            <year>2007</year>
          </date>
          <fpage>349</fpage>
          <lpage>55</lpage>
          <issue>2</issue>
          <volume>188</volume>
          <person-group person-group-type="author">
            <name>
              <surname>McCann</surname>
              <given-names>GP</given-names>
            </name>
            <name>
              <surname>Gan</surname>
              <given-names>CT</given-names>
            </name>
            <name>
              <surname>Beek</surname>
              <given-names>AM</given-names>
            </name>
            <name>
              <surname>Niessen</surname>
              <given-names>HW</given-names>
            </name>
            <name>
              <surname>Vonk Noordegraaf</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>van Rossum</surname>
              <given-names>AC</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B6">
        <mixed-citation>6. Shiozaki AA, Senra T, Arteaga E, Martinelli Filho M, Pita CG, Avila LF, et al. Myocardial fibrosis detected by cardiac ct predicts ventricular fibrillation/ventricular tachycardia events in patients with hypertrophic cardiomyopathy. JACC Cardiovasc Imaging.2013;7(3):173-81.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Myocardial fibrosis detected by cardiac ct predicts ventricular fibrillation/ventricular tachycardia events in patients with hypertrophic cardiomyopathy</article-title>
          <source>JACC Cardiovasc Imaging</source>
          <date>
            <year>2013</year>
          </date>
          <fpage>173</fpage>
          <lpage>81</lpage>
          <issue>3</issue>
          <volume>7</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Shiozaki</surname>
              <given-names>AA</given-names>
            </name>
            <name>
              <surname>Senra</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Arteaga</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Martinelli Filho</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Pita</surname>
              <given-names>CG</given-names>
            </name>
            <name>
              <surname>Avila</surname>
              <given-names>LF</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B7">
        <mixed-citation>7. Shiozaki AA, Senra T, Arteaga E, Pita CG, Martinelli Filho M, Avila LF,et al.  [myocardial fibrosis in patients with hypertrophic cardiomyopathy and high risk for sudden death ]. Arq Bras Cardiol.2010;94(4):535-40.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>myocardial fibrosis in patients with hypertrophic cardiomyopathy and high risk for sudden death</article-title>
          <source>Arq Bras Cardiol</source>
          <date>
            <year>2010</year>
          </date>
          <fpage>535</fpage>
          <lpage>40</lpage>
          <issue>4</issue>
          <volume>94</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Shiozaki</surname>
              <given-names>AA</given-names>
            </name>
            <name>
              <surname>Senra</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Arteaga</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Pita</surname>
              <given-names>CG</given-names>
            </name>
            <name>
              <surname>Martinelli Filho</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Avila</surname>
              <given-names>LF</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B8">
        <mixed-citation>8. Mello RP, Szarf G, Schvartzman PR, Nakano EM, Espinosa MM, Szejnfeld D,et al. Delayed enhancement cardiac magnetic resonance imaging can identify the risk for ventricular tachycardia in chronic chagas' heart disease. Arq Bras Cardiol.2012;98(5):421-30.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Delayed enhancement cardiac magnetic resonance imaging can identify the risk for ventricular tachycardia in chronic chagas' heart disease</article-title>
          <source>Arq Bras Cardiol</source>
          <date>
            <year>2012</year>
          </date>
          <fpage>421</fpage>
          <lpage>30</lpage>
          <issue>5</issue>
          <volume>98</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Mello</surname>
              <given-names>RP</given-names>
            </name>
            <name>
              <surname>Szarf</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Schvartzman</surname>
              <given-names>PR</given-names>
            </name>
            <name>
              <surname>Nakano</surname>
              <given-names>EM</given-names>
            </name>
            <name>
              <surname>Espinosa</surname>
              <given-names>MM</given-names>
            </name>
            <name>
              <surname>Szejnfeld</surname>
              <given-names>D</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B9">
        <mixed-citation>9. Mahrholdt H, Wagner A, Deluigi CC, Kispert E, Hager S, Meinhardt G, et al.. Presentation, patterns of myocardial damage, and clinical course of viral myocarditis. <italic>Circulation</italic>. 2006;114(15):1581-90.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Presentation, patterns of myocardial damage, and clinical course of viral myocarditis</article-title>
          <source>Circulation</source>
          <date>
            <year>2006</year>
          </date>
          <fpage>1581</fpage>
          <lpage>90</lpage>
          <issue>15</issue>
          <volume>114</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Mahrholdt</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Wagner</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Deluigi</surname>
              <given-names>CC</given-names>
            </name>
            <name>
              <surname>Kispert</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Hager</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Meinhardt</surname>
              <given-names>G</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B10">
        <mixed-citation>10. Shehata ML, Lossnitzer D, Skrok J, Boyce D, Lechtzin N, Mathai SC, et al.. Myocardial delayed enhancement in pulmonary hypertension: Pulmonary hemodynamics, right ventricular function, and remodeling. AJR Am J Roentgenol.2011;196(1):87-94.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Myocardial delayed enhancement in pulmonary hypertension: Pulmonary hemodynamics, right ventricular function, and remodeling</article-title>
          <source>AJR Am J Roentgenol</source>
          <date>
            <year>2011</year>
          </date>
          <fpage>87</fpage>
          <lpage>94</lpage>
          <issue>1</issue>
          <volume>196</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Shehata</surname>
              <given-names>ML</given-names>
            </name>
            <name>
              <surname>Lossnitzer</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Skrok</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Boyce</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Lechtzin</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Mathai</surname>
              <given-names>SC</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B11">
        <mixed-citation>11. Armstrong AC, Bandeira AM, Correia LC, Melo HC, Silveira CA, Albuquerque E, et al. Pulmonary artery pressure, gender, menopause, and pregnancy in schistosomiasis-associated pulmonary hypertension. Arq Bras Cardio.2013;101(2):154-9.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Pulmonary artery pressure, gender, menopause, and pregnancy in schistosomiasis-associated pulmonary hypertension</article-title>
          <source>Arq Bras Cardio</source>
          <date>
            <year>2013</year>
          </date>
          <fpage>154</fpage>
          <lpage>9</lpage>
          <issue>2</issue>
          <volume>101</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Armstrong</surname>
              <given-names>AC</given-names>
            </name>
            <name>
              <surname>Bandeira</surname>
              <given-names>AM</given-names>
            </name>
            <name>
              <surname>Correia</surname>
              <given-names>LC</given-names>
            </name>
            <name>
              <surname>Melo</surname>
              <given-names>HC</given-names>
            </name>
            <name>
              <surname>Silveira</surname>
              <given-names>CA</given-names>
            </name>
            <name>
              <surname>Albuquerque</surname>
              <given-names>E</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
    </ref-list>
  </back>
  <sub-article article-type="translation" id="TRen" xml:lang="en">
    <front-stub>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Editorial</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title xml:lang="en">Myocardial delayed enhancement by cardiac magnetic resonance imaging in Pulmonary Arterial Hypertension: a marker of disease severity</article-title>
      </title-group>
    </front-stub>
    <body>
      <p>
        <bold>EDITORIAL</bold>
      </p>
      <p>
        <fn id="enda-body2">
          <label>
            <bold>Myocardial delayed enhancement by cardiac magnetic resonance imaging in Pulmonary Arterial Hypertension: a marker of disease severity</bold>
          </label>
          <p>
            <bold>Carlos Eduardo Rochitte<sup>I</sup>; Susana Hoette<sup>II</sup>; Rog&#233;rio Souza<sup>II</sup></bold>
          </p>
        </fn>
      </p>
      <p><sup>I</sup>Instituto do Cora&#231;&#227;o, InCor, Setor de Resson&#226;ncia Magn&#233;tica e Tomografia Computadorizada Cardiovascular</p>
      <p><sup>II</sup>Unidade de Circula&#231;&#227;o Pulmonar, Pneumologia, Instituto do Cora&#231;&#227;o do Hospital das Cl&#237;nicas da FMUSP, S&#227;o Paulo, SP - Brazil</p>
      <p>Mailing Address</p>
      <p><bold>Keywords:</bold> Magnetic Resonance Secfroscopy/methods; Hypertension, Pulmonary; Myocardium; Endomyocardial Fibrosis.</p>
      <p>The study of Bessa et al.<sup>1</sup>, published in this issue of <italic>Arquivos Brasileiros de Cardiologia</italic>, studied 30 patients with pulmonary hypertension (PH) using cardiac magnetic resonance imaging. They evaluated the presence and extent of delayed enhancement in these patients and correlated the percentage of delayed enhancement mass with severity markers in pulmonary hypertension. Delayed enhancement was found in 93% of patients with HP in the anterior and inferior septa, in the septal-RV free wall attachment zones, commonly called delayed enhancement of ventricular junction pattern. The delayed enhancement mass was corrected to the left ventricular mass. The percentage of delayed enhancement was then used for analysis. This study showed a higher percentage of myocardial fibrosis in patients with signs of Right Ventricular Failure (RVF), Functional Class (FC) IV, 6-Minute Walk Test (6MWT) &lt; 300 m, Cardiac Index (CI) &lt; 2.0 and right atrial pressure &gt; 15. The presence of RHF, the impairment of FC and the 6MWT walking distance and low CI are classic markers of prognosis in HP. The percentage of fibrosis was able to identify patients with RVF (clinical evaluation), FC IV, 6MWT &lt; 300 m and CI &lt; 2.0 L/min.m<sup>2</sup> with good accuracy.</p>
      <p>Despite some progress in understanding the physiopathology of the disease and the discovery of new treatments in recent decades, pulmonary hypertension is still a disease with poor prognosis<sup>2</sup>. Non-invasive markers to better assess the severity of the disease and that may help determine which patients require more aggressive treatments are needed. Delayed enhancement is a tool that was initially used to evaluate areas of myocardial fibrosis in patients who have had myocardial infarction. The contrast injected is quickly rinsed in normal areas, but when there is increased extracellular tissue, such as in fibrosis, the contrast is retained and is slowly eliminated from these areas. When images are acquired late (5-10 min after contrast injection), the areas in which the myocardium is intact do not retain the contrast, but the areas with fibrosis retain the contrast, hence the term delayed enhancement.</p>
      <p>In patients with HP, three studies demonstrated the presence of delayed enhancement in most patients and delayed enhancement was found mainly in the RV septal attachment zone and in the septal wall<sup>3-5</sup>. Fibrosis in these areas can also be found in hypertrophic cardiomyopathy<sup>6,7</sup>, unlike other cardiomyopathies such as the Chagas disease<sup>8</sup>, with predominance of fibrosis in the basal and apical left ventricular (LV) inferolateral wall, or viral myocarditis with diffuse pattern<sup>9</sup>, among other patterns suggestive of specific etiologies of cardiomyopathies. In most of these diseases, the presence of delayed enhancement appears to be associated with increased risk of arrhythmias and worse prognosis. Delayed myocardial enhancement (fibrosis) of ventricular junction pattern appears to be associated with Right Ventricular (RV) overload. An explanation for this preferential location of delayed enhancement is the overhead sustained by the septum with increased RV afterload. As the RV overload increases, it dilates and pushes the septum toward the LV, overloading the septal RV attachment zones and the septum itself. Shehata et al. demonstrated the inverse relationship of delayed enhancement mass with Eccentricity Index (EI), that is, the higher the septal bulging toward the left ventricle, and consequently the lower the EI, the greater the delayed enhancement mass<sup>10</sup>. In experimental studies, these are the areas subjected to maximum stress in normal ventricular contraction, and these areas are also the first to produce natriuretic peptide type A in HP models, reflecting greater mechanical stress. The study of Bessa et al. demonstrated that most patients with HP had delayed enhancement and ventricular junction pattern, confirming the literature data<sup>1</sup>. An echocardiographic study in patients with HP of a specific etiology associated with schistosomiasis also demonstrated a relationship of increased pulmonary pressure with disease severity, suggesting that in various etiologies of HP, a delayed enhancement of similar pattern may occur (Armstrong)<sup>11</sup>.</p>
      <p>The strength of this study was that all patients underwent right cardiac catheterization within 72 hours after cardiac magnetic resonance imaging. Previous studies have shown the relationship of delayed enhancement mass with RV dysfunction and hemodynamic variables, but this study was the first to demonstrate the relationship of myocardial fibrosis with clinical, hemodynamic and functional markers. </p>
      <p>The evaluation of right ventricular function is emerging as an independent prognostic marker in HP and the study of Sheata et al. also demonstrated an inverse correlation of delayed enhancement mass with RV ejection fraction<sup>10</sup>. Unfortunately, this study did not evaluate the fibrosis mass percentage in relation to RV dysfunction.</p>
      <p>Although this study has evaluated a small number of patients with HP and although it is a cross-sectional study in which it is not possible to show the prognostic role of delayed enhancement, the fact that the percentage of fibrosis is increased in patients who have markers of worse prognosis suggests that delayed enhancement may prove to be an important noninvasive prognostic marker in patients with HP. It would be interesting if the authors conducted long-term follow-up of these patients, so that the prognostic role of delayed enhancement is confirmed and fibrosis may show its prognostic role in HP, thus helping clinical decisions. The study of Bessa et al. also opens up the possibility of comparing other forms of HP, such as those belonging to the other groups of classification (secondary to left ventricular dysfunction, diseases of the pulmonary parenchyma, chronic pulmonary thromboembolism, for example) in order to analyze the existence or not of different patterns of fibrosis.</p>
      <p>Despite these limitations, the manuscript of Bessa et al. is another original scientific contribution indicating that myocardial fibrosis detected by cardiac resonance imaging correlates directly with the severity of disease and possibly with prognosis. Therefore, another marker of severity of cardiomyopathy associated with pulmonary hypertension is reaffirmed and can be identified by magnetic resonance imaging. The evaluation of interstitial myocardial fibrosis through myocardial T1 mapping by resonance imaging may bring in the future more information on the myocardial state and prognosis in this important and challenging clinical scenario.</p>
      <p>
        <bold>References</bold>
      </p>
    </body>
  </sub-article>
</article>
